Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial

Published:2017-12-18 Issue:4 Volume:20 Page:1044-1049
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Chen Yingli¹,Liu Xiaomin²,Li Quanmin³,Ma Jianhua⁴,Lv Xiaofeng⁵,Guo Lixin⁶,Wang Changjiang⁷,Shi Yongquan⁸,Li Yanbing⁹^ORCID,Johnsson Eva¹⁰,Wang Mei¹¹,Zhao June¹²,Ji Linong¹^ORCID

Affiliation:

1. Department of Endocrinology and Metabolism; Peking University People's Hospital; Beijing China

2. Department of Endocrinology; First Affiliated Hospital of Harbin Medical University; Harbin China

3. Department of Endocrinology; The General Hospital of the PLA Rocket Force; Beijing China

4. Department of Endocrinology; Nanjing First Hospital; Nanjing China

5. PLA General Hospital of Beijing Military Region; Beijing China

6. Department of Endocrinology; Beijing Hospital, National Center of Gerontology; Beijing China

7. Department of Endocrinology; First Affiliated Hospital of Anhui Medical University; Hefei China

8. Department of Endocrinology; Shanghai Changzheng Hospital; Shanghai China

9. Department of Endocrinology; First Affiliated Hospital of Sun Yat-sen University; Guangzhou China

10. AstraZeneca Gothenburg; Mölndal Sweden

11. China Development Unit; AstraZeneca; Beijing China

12. AstraZeneca; Gaithersburg Maryland

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13161/fullpdf

Reference19 articles.

1. Prevalence and control of diabetes in Chinese adults;Xu;JAMA,2013

2. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetes Care,2015

3. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors;Nauck;Diabetes Obes Metab,2016

4. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus;Tahrani;Adv Ther,2009

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Individual dipeptidyl peptidase‐4 inhibitors and acute kidney injury in patients with type 2 diabetes: A systematic review and network meta‐analysis;Basic & Clinical Pharmacology & Toxicology;2024-05-02

2. Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;Journal of Clinical Medicine;2024-03-20

3. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials;BMJ;2022-06-28

4. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors;Current Drug Safety;2021-06-08

5. Efficacy and safety of linagliptin as add‐on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled trial;Diabetes, Obesity and Metabolism;2020-11-06